Efficacy of first‐line immunochemotherapy across KRAS mutation subtypes in advanced lung adenocarcinoma

International Journal of Cancer 2026 Open access

Read full text
Authors: Hongping Jin, H. Huang, Yue Wu, Yidan Zhang, Jianlin Xu, Tengfei Liu, Hua Zhong, Qian Miao, Runbo Zhong
DOI: 10.1002/ijc.70362
Cited by: 1
References: 36

Abstract

The impact of KRAS mutation subtypes on treatment response to first-line immunochemotherapy in advanced lung adenocarcinoma (LUAD) remains uncertain. This study evaluated treatment efficacy across KRAS subtypes and examined the role of programmed death-ligand 1 (PD-L1) expression and co-mutations. We retrospectively analyzed 335 patients with advanced KRAS-mutant LUAD treated with first-line immunochemotherapy between 2018 and 2022 at two centers. Patients were categorized into G12A (n = 36), G12C (n = 116), G12D (n = 62), G12V (n = 56), and other subtypes (n = 65). PD-L1 tumor proportion score (TPS) was stratified as

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers Lung Cancer Research Studies

Publication details

Journal / source
International Journal of Cancer
Publisher
Wiley
Volume
158
Issue
12
Pages
3187–3196
Publication date
3 February 2026
Language
EN